{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:02:45Z","timestamp":1792389765408,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1245\/s10434-019-07549-8","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:02:50Z","timestamp":1563966170000},"page":"3025-3031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":295,"title":["Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons"],"prefix":"10.1245","volume":"26","author":[{"given":"Eric R.","family":"Manahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Euhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Boolbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walton A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"7549_CR1","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-019-07341-8","volume":"26","author":"J Plichta","year":"2019","unstructured":"Plichta, J, Sebastian, M, Hughes, K, et al. Germline genetic testing: what the breast surgeon needs to know. Ann of Surg Oncol. 2019;26:2184\u201390.","journal-title":"Ann of Surg Oncol."},{"key":"7549_CR2","unstructured":"National Cancer Institute. Cancer Stat Fact Sheets. \n                    http:\/\/seer.cancer.gov\/\n                    \n                   Accessed 10 Jan 2019."},{"key":"7549_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature."},{"key":"7549_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/ejhg.2014.16","volume":"22","author":"L Castera","year":"2014","unstructured":"Castera L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22:1305\u201313.","journal-title":"Eur J Hum Genet."},{"key":"7549_CR5","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.1073\/pnas.1007983107","volume":"107","author":"T Walsh","year":"2010","unstructured":"Walsh T, Lee MK, Casadei S, et al. Detection of inherited pathogenic variants for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA. 2010;107:12629\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7549_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13402-011-0010-3","volume":"34","author":"P van der Groep","year":"2011","unstructured":"van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71\u201388.","journal-title":"Cell Oncol (Dordr)."},{"key":"7549_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","volume":"11","author":"T Walsh","year":"2007","unstructured":"Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11:103\u20135.","journal-title":"Cancer Cell."},{"key":"7549_CR8","first-page":"323","volume":"108","author":"A Meindl","year":"2011","unstructured":"Meindl A, Ditsch N, Kast K, Schmutzler RK. Hereditary breast and ovarian cancer: New genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108:323\u201330.","journal-title":"Dtsch Arztebl Int."},{"key":"7549_CR9","unstructured":"National Research Genome Institute (NIH). Learning about the BRCAX study. \n                    http:\/\/www.genome.gov\/10000532\n                    \n                  . Accessed 10 Jan 2019."},{"key":"7549_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 pathogenic variant carriers with cancer risk and mortality. JAMA. 2010;304:967\u201375.","journal-title":"JAMA."},{"key":"7549_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 pathogenic variant. N Engl J Med. 2002;346:1609\u201315.","journal-title":"N Engl J Med."},{"key":"7549_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene pathogenic variant carriers. J Natl Cancer Inst. 2001;93:1633\u20137.","journal-title":"J Natl Cancer Inst."},{"key":"7549_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian AW, Sigal BM, Plevrittis SK. Survival analysis of cancer risk reduction strategies for BRCA1\/2 pathogenic variant carriers. J Clin Oncol. 2010;28:222\u201331.","journal-title":"J Clin Oncol."},{"key":"7549_CR14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1200\/JCO.2005.10.035","volume":"23","author":"SA Narod","year":"2005","unstructured":"Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23:1656\u201363.","journal-title":"J Clin Oncol."},{"key":"7549_CR15","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A, Lubinski J, KlijnJ, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers: international case-control study. J Clin Oncol. 2005;23:7491\u20136.","journal-title":"J Clin Oncol"},{"key":"7549_CR16","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 pathogenic variant carriers: a case-control study. Lancet. 2000;356:1876\u201381.","journal-title":"Lancet."},{"key":"7549_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 pathogenic variants. N Engl J Med. 2002;346:1616\u201322.","journal-title":"N Engl J Med."},{"key":"7549_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: The PROSE Study Group. J Clin Oncol. 2004;22:1055\u201362.","journal-title":"J Clin Oncol."},{"key":"7549_CR19","first-page":"1","volume":"37","author":"PD Beitsch","year":"2018","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37:1\u20138.","journal-title":"J Clin Oncol."},{"key":"7549_CR20","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S, Axilbund JE, O\u2019Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25:2925\u201331.","journal-title":"Ann Surg Oncol."},{"key":"7549_CR21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"Kurian","year":"2019","unstructured":"Kurian et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019:37;1305\u201315.","journal-title":"J Clin Oncol."},{"key":"7549_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0446-1","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019. \n                    https:\/\/doi.org\/10.1038\/s41416-019-0446-1\n                    \n                  .","journal-title":"Br J Cancer"},{"key":"7549_CR23","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1245\/s10434-015-4754-2","volume":"22","author":"NS Kapoor","year":"2015","unstructured":"Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1\/2 pathogenic variants and has a higher diagnostic yield compared to limited BRCA1\/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22:3282\u20138.","journal-title":"Ann Surg Oncol."},{"key":"7549_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","volume":"31","author":"SM Domchek","year":"2013","unstructured":"Domchek, SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267\u201370.","journal-title":"J Clin Oncol."},{"key":"7549_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","volume":"23","author":"JE Garber","year":"2005","unstructured":"Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23:276\u201392.","journal-title":"J Clin Oncol."},{"key":"7549_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semradonc.2010.08.008","volume":"21","author":"LJ Pierce","year":"2011","unstructured":"Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol. 2011;21:43\u201350.","journal-title":"Semin Radiat Oncol."},{"key":"7549_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11912-014-0428-7","volume":"17","author":"WM Sikov","year":"2015","unstructured":"Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep. 2015;17:3.","journal-title":"Curr Oncol Rep."},{"key":"7549_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"L Livraghi","year":"2015","unstructured":"Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.","journal-title":"BMC Med."},{"key":"7549_CR29","unstructured":"Hughes KS, Parmigiani G, Braun DP. All syndromes known to man evaluator. 2018; \n                    www.ask2me.org\n                    \n                  . Accessed 13 Aug 2018."},{"key":"7549_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 pathogenic variants detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117\u201330.","journal-title":"Am J Hum Genet."},{"key":"7549_CR31","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","volume":"77","author":"EB Claus","year":"1996","unstructured":"Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318\u201324.","journal-title":"Cancer."},{"issue":"23","key":"7549_CR32","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","volume":"34","author":"MK Schmidt","year":"2016","unstructured":"Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750\u201360.","journal-title":"J Clin Oncol."},{"issue":"1","key":"7549_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/gm12","volume":"1","author":"RL Milne","year":"2009","unstructured":"Milne RL. Variants in the ATM gene and breast cancer susceptibility. Genome Med. 2009;1(1):12.","journal-title":"Genome Med."},{"key":"7549_CR34","unstructured":"Stanford Medicine Cancer Institute. Decision tool for women with BRCA pathogenic variants. \n                    http:\/\/brcatool.stanford.edu\/brca.html\n                    \n                  . Accessed Jan 2019."},{"key":"7549_CR35","unstructured":"American College of Surgeons. Cancer. \n                    http:\/\/www.facs.org\/cancerprogram\/index.html\n                    \n                  . Accessed Jan 10 2019."},{"key":"7549_CR36","unstructured":"Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force Recommendation. Evidence syntheses, no. 101. 2013. \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK179201\/\n                    \n                  . Accessed 10 Jan 2019."},{"key":"7549_CR37","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian. NCCN clinical practice guidelines in oncology. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf\n                    \n                  . Accessed Feb 1 2019."},{"key":"7549_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/M13-1684","volume":"160","author":"H Nelson","year":"2014","unstructured":"Nelson H, Pappas M, Zakher B, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160:255\u201366.","journal-title":"Ann Intern Med"},{"key":"7549_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11912-013-0371-z","volume":"16","author":"IR Rainville","year":"2014","unstructured":"Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep. 2014;16:371.","journal-title":"Curr Oncol Rep."},{"key":"7549_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/cge.12028","volume":"83","author":"CS Ku","year":"2013","unstructured":"Ku CS, Cooper DN, Iacopetta B, et al. Integrating next generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet. 2013; 83:2\u20136.","journal-title":"Clin Genet."},{"key":"7549_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5858\/arpa.2013-0710-OA","volume":"139","author":"B Simen","year":"2015","unstructured":"Simen B, Yin L, Goswami C, et al. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. Arch Pathol Lab Med. 2015;139:508\u201317.","journal-title":"Arch Pathol Lab Med."},{"key":"7549_CR42","unstructured":"Association for Molecular Pathology v Myriad Genetics, Inc., 569 US (2013)."},{"key":"7549_CR43","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/jnci\/djt342","volume":"105","author":"A Azvolinsky","year":"2013","unstructured":"Azvolinsky A. Supreme Court ruling broadens BRCA testing options. J Natl Cancer Inst. 2013;105:1671\u201372.","journal-title":"J Natl Cancer Inst."},{"key":"7549_CR44","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/gim.2014.40","volume":"16","author":"H LaDuca","year":"2014","unstructured":"LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16:830\u20137.","journal-title":"Genet Med."},{"key":"7549_CR45","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32:2001\u20139.","journal-title":"J Clin Oncol."},{"key":"7549_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, et al. Frequency of pathogenic variants in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25\u201333.","journal-title":"Cancer."},{"key":"7549_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/cge.12488","volume":"88","author":"A Yorczyk","year":"2015","unstructured":"Yorczyk A, Robinson LS, Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clin Genet. 2015;88:278\u201382.","journal-title":"Clin Genet."},{"key":"7549_CR48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jama.2014.12483","volume":"312","author":"MC King","year":"2014","unstructured":"King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA. 2014;312:1091\u20132.","journal-title":"JAMA."},{"key":"7549_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07549-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07549-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07549-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T19:11:00Z","timestamp":1595445060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07549-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["7549"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07549-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kevin Hughes reports honoraria from Focal Therapeutics, 23andMe, and is a founder of and has a financial interest in CRA Health (Formerly Hughes RiskApps); Mark Robson reports honoraria (advisory) from AstraZeneca, and consulting or advisory from: McKesson, AstraZeneca, Merck (uncompensated), research funding from: AstraZeneca (Institution), Myriad (Institution, in-kind), Invitae (Institution, in-kind), AbbVie (institution), Tesaro (institution), Medivation (institution) and travel or accommodation or expenses from AstraZeneca; Dr. Banu Arun reports research funding from: AstraZeneca (institution), Invitae (institution), AbbVie (institution), and PharmaMar (institution).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}